Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16412396 | 0.81 | CMA1 (0.46) | MEN1KMT2ACMA1AHRPIM1 | |
| SCHEMBL30462531 | 0.81 | CMA1 (0.46) | MEN1KMT2ACMA1AHRPIM1 | |
| SCHEMBL1223198 | 0.81 | PDK2 (0.55) | MEN1KMT2ACMA1AHRPIM1 | |
| SCHEMBL29519108 | 0.81 | PDK2 (0.55) | MEN1KMT2ACMA1AHRPIM1 | |
| SCHEMBL2266416 | 0.79 | PKM (0.47) | CMA1AHRHTR6AKR1B1CES1 | |
| SCHEMBL2266409 | 0.79 | PKM (0.47) | CMA1AHRHTR6AKR1B1CES1 | |
| SCHEMBL31440532 | 0.79 | MEN1 (0.52) | MEN1KMT2ACMA1AHRPIM1 | |
| SCHEMBL19905697 | 0.79 | PKM (0.47) | CMA1AHRHTR6AKR1B1CES1 | |
| SCHEMBL11829 | 0.79 | MEN1 (0.52) | MEN1KMT2ACMA1AHRPIM1 | |
| SCHEMBL29502068 | 0.79 | MEN1 (0.52) | MEN1KMT2ACMA1AHRPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630516-B2 | Compounds | NRG THERAPEUTICS LTD. (GB) | 2026-05-19 | — | — | US | disclosed |
| EP-4208442-B1 | MPTP INHIBITORS | NRG THERAPEUTICS LTD (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| EP-4486721-A1 | ACRYLAMIDE COMPOUNDS | NRG Therapeutics LTD (GB) | 2025-01-08 | — | — | EP | disclosed |
| CN-118804911-A | Acrylamide compound | NRG治疗有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| WO-2023166303-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166303-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-09-07 | — | — | WO | disclosed |
| EP-4208442-A1 | NOVEL COMPOUNDS | NRG Therapeutics LTD (GB) | 2023-07-12 | — | — | EP | disclosed |
| CN-116096705-A | Novel compounds | NRG治疗有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2022049376-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630516-B2 | Compounds | CYP4B1, CYP1B1, NR4A1 | MEN1 1126/4885KMT2A 761/4885CMA1 2165/4885 |
| US-20240067614-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, CXCR2 | MEN1 661/4885KMT2A 4448/4885CMA1 1525/4885 |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | ACR, CCNI, FANCI | MEN1 699/4885KMT2A 3787/4885CMA1 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.